RBC reiterates target for Surgery Partners stock at USD 19.00

Published on 10/07/2026 at 02:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue guidance for 2026 is USD 3.08-3.18 billion. Surgery Partners stock has adjusted EBITDA guidance of at least USD 489 million.

SGRY, US86881A1007, Illustration mit AI erstellt.

Surgery Partners, Inc. (ISIN US86881A1007) is carrying a USD 19.00 price target from RBC Capital after the research house reiterated its Outperform rating, as TradingView reports. The more immediate operating change came on September 17, 2026, when Surgery Partners completed the sale of interests in two Idaho hospitals and revised its 2026 outlook.

Sale reshapes the 2026 outlook

According to Ambulatory Surgery Center News on September 17, 2026, Surgery Partners received USD 797 million in gross proceeds and USD 587 million in net cash proceeds from the transaction. Management said the proceeds would primarily be used to reduce debt, giving the divestiture a balance-sheet role beyond the portfolio shift.

The revised 2026 revenue guidance is USD 3.08 billion-USD 3.18 billion, compared with the previous USD 3.35 billion-USD 3.45 billion range. Adjusted EBITDA guidance is at least USD 489 million, down from the previous minimum of USD 530 million, reflecting the removal of the Idaho Falls facilities from the outlook.

Higher focus, lower reported scale

On a pro forma basis excluding Idaho Falls, Surgery Partners guided to 2026 revenue of USD 2.60 billion-USD 2.67 billion and adjusted EBITDA of at least USD 414 million, according to Ambulatory Surgery Center News. The comparison separates the continuing surgical platform from the revenue and earnings contribution that has now left the group.

The company describes its model as an outpatient healthcare network spanning more than 300 locations in 30 states, including ambulatory surgery centers, surgical hospitals, physician practices and urgent care facilities, according to its investor-relations page. The strategic trade-off is visible in the numbers: lower consolidated guidance in exchange for a narrower operating portfolio and debt-reduction proceeds.

Euro reference remains dated

The last Lang & Schwarz data point for Surgery Partners showed a prior close of EUR 11.95 for October 5, 2026. Finance data placed the Nasdaq-listed company at a USD 1.8 billion market capitalization on October 6, 2026, with a 52-week range of USD 11.41 to USD 23.44.

The further course of trading is shown by the continuously updated real-time quote of Surgery Partners stock.